Drug Trial Radar · NCT04422509
Lanadelumab for Treatment of COVID-19 Disease
Last checked: Nov 20, 2026Latest source record: Jul 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
43
Actual
Start
Oct 30, 2020
Primary completion
Feb 25, 2021
Study completion Apr 30, 2021
Sponsor
- Lead sponsor
- Radboud University Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Takeda
- First posted
- Jun 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
So far little is very few drugs have demonstrated positive results for treatment of COVID19. Recently the researchers have shown that the use of icatibant in COVID-19 results in a potent decrease in oxygen use. Yet the effect of the three dosages as according to the label dose was insufficient to maintain the clinical improvement in a small group of patients. The researchers argue that with the use of lanadelumab a more lasting effect can be reached due to its longer half life.
Conditions
- COVID-19
Interventions
lanadelumabBiological
single dose, or two doses administered iv
regular careOther
no lanadelumab administration, treated according to regular care
Primary outcomes
What the sponsor says the trial is designed to measure.
- oxygenTime frame: 2 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Amsterdam UMC
Amsterdam, Netherlands
Rijnstate hospital
Arnhem, Netherlands
Radboudumc
Nijmegen, Netherlands
UMC Utrecht
Utrecht, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.